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erythematosusAbstract Introduction: The link between rheumatoid arthritis (RA), systemic lupus erythemato-
sus (SLE) and gene polymorphism of the signal transducers and activators of transcription 4
(STAT4) has been proved in different populations.
Aim of the work: Investigation of the possible association of STAT4 rs7574865(G/T) polymor-
phism with RA and SLE patients and the signiﬁcance of its relation to the diseases activity and
severity.
Patients and methods: Fifty RA patients, 50 SLE patients and 50 healthy controls were included.
STAT4 genotyping was performed by restriction fragment length polymorphism–polymerase chain
reaction.
Results: In both RA and SLE patients, the frequencies of STAT4(GT) genotype were signiﬁ-
cantly increased compared to controls (46%,48% and 26% respectively). There was a signiﬁcant
difference in the distribution of the T allele between RA and SLE patients with the controls
(37%, 40% vs 17%). Patients carrying the T-allele had a high risk for RA and SLE in comparison
with the healthy control (p= 0.0001). RA patients with the TT genotype had signiﬁcantly higher
levels of the erythrocyte sedimentation rate, C-Reactive protein, anti-cyclic citrullinated peptide,
disease activity score (DAS28) and modiﬁed Sharp/van der Heijde score compared to those with
GG and GT genotypes. The TT genotype in SLE signiﬁcantly correlated with low complement
(C3,C4), proteinuria, anti-double stranded deoxyribonucleic acid (dsDNA), photosensitivity and
damage index.
22 H.M. El-Saadany et al.Conclusions: STAT4 polymorphism was associated with an increased risk of RA and SLE
patients, so it may be a common genetic risk factor for both diseases. Moreover RA, SLE patients
who are homozygous for the T-allele are susceptible to have increased disease activity and severity.
 2016 Production and hosting by Elsevier B.V. on behalf of Egyptian Society of Rheumatic Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-
nd/4.0/).1. Introduction
Rheumatoid arthritis (RA) and systemic lupus erythematosus
(SLE) are autoimmune diseases characterized by the develop-
ment of immune response against self antigens. Although
etiology remains a mystery, a lot of studies proved that the
genetic factors have an important association with these
autoimmune diseases in combination with environmental fac-
tors and immune dysregulation [1]. Genetic association of
HLA-DRB1 and RA has been well established in multiple
ethnic groups. However, the HLA region only contributes to
30–50% of the genetic component for RA [2]. Several risk
genes and susceptibility polymorphisms outside the HLA
region have been identiﬁed in RA and SLE but seem to have
a unique association with speciﬁc ethnic groups [3]. Cytokine
gene polymorphisms in Egyptian patients have been reported
in RA [4–6] and SLE [7–9].
Several studies have documented a strong association
between the signal transducer and activator of transcription 4
(STAT4) single-nucleotide polymorphism (SNP) and both RA
and SLE in European and Asian populations and considered
a risk factor for both diseases similar to HLA-DRB1 [10–13].
The role of STAT4 gene polymorphism in SLE has also been
studied in a group of Egyptian patients and reported to be a
possibly important determinant of disease progression [14].
STAT4 mediates the intracellular signal activation by sev-
eral cytokines such as interleukin 12 (IL-12), IL-23, IL-27
and type I interferons (IFNs) [15]. It has been reported to be
critical for IL-12-dependent T helper 1 (Th1) differentiation
and IFN-c production and to be required for the development
of IL-23-primed IL-17-secreting cells (Th17 cells) [16,17]. So
STAT4 plays a crucial role in the differentiation and prolifer-
ation of both Th1 and Th17 cells [15,17] which are main effec-
tors in RA and SLE [18].
STAT4 gene maps to chromosome 2q33. The STAT4
rs7574865 polymorphism is located within the third intron of
the gene and shows the strongest association with autoimmu-
nity [19]. The allelic frequencies of genes often differ between
populations.
Up till now, there are limited resources and studies concern-
ing the detection of STAT4 polymorphism in the Egyptian pop-
ulation. So the aim of this study is to investigate the possible
association of STAT4 rs7574865 gene polymorphism with the
susceptibility to RA and SLE in Egyptian patients and to study
its signiﬁcance in relation to the disease activity and severity.
2. Patients and methods
2.1. Subjects
This study included 50 patients with RA diagnosed according
to the 2010 ACR/EULAR classiﬁed criteria for RA [20].They were 9 males and 41 females, their ages ranged from 21
to 65 years with a mean of 39.91 ± 13.5 years; their mean dis-
ease duration was 6.41 ± 5.2 years and included 50 SLE
patients diagnosed according to Systemic Lupus International
Collaborating Clinics classiﬁcation criteria for SLE [21]. They
were 10 males and 40 females, their ages ranged from 20 to
45 years with a mean of 27.78 ± 6.8 years; their mean disease
duration was 5.3 ± 3.2 years. In addition, 50 apparently
healthy volunteers served as controls; their ages and ethnic ori-
gin were matched with the patients, their ages ranged from 21 to
65 years with amean of 37.39 ± 9.3 years. All patients and con-
trols were recruited from the Outpatients Clinic of Physical
Medicine, Rheumatology and Rehabilitation and Internal
Medicine departments, Tanta University Hospitals. Informed
consent was obtained from all patients and controls. This study
protocol was approved by the ethics committee of the Faculty
of Medicine, Tanta University.
2.2. Clinical assessment
Patients were subjected to complete history taking, thorough
clinical examination with locomotor examinations preformed.
As regards RA patients, tender joint count (TJC) and swollen
joint count (SJC) were assessed and disease activity was
determined by disease activity score in 28 joints (DAS28)
[22]. X-rays of both hands and feet were obtained in all
patients to be predictive of disease progression and were scored
according the Sharp/van der Heijde modiﬁed score [23]. Func-
tional disability in the RA patients was determined by the
Health Assessment Questionnaire (HAQ) [24]. For SLE
patients the disease activity was assessed according to SLE dis-
ease activity index (SLEDAI) [25].
2.3. Laboratory data
Blood samples (10 ml) were drawn from all patients and
controls. On the day of sampling, the following laboratory
investigations were performed for all RA patients: complete
blood count (CBC), erythrocyte sedimentation rate (ESR),
sera were separated immediately for assessment of the
C-reactive protein (CRP) by latex agglutination, rheumatoid
factor (RF) by slide haemagglutination Rose–Waaler test
and the rest stored at 20 C for the assessment of
cyclic citrullinated peptides (anti-CCP) using the commercial
anti-CCP2 test (DIASTAT, Axis-Shield, Dundee, United
Kingdom) by enzyme-linked immunosorbent assay (ELISA).
The assay was performed according to the manufacturer’s
instructions, a concentration >5 IU/ml was considered
positive.
For SLE patients, on the day of sampling the following lab-
oratory assessments were done: complete urine analysis with
24 h protein collection and total leukocytic count. Stored serum
Association of STAT4 rs7574865(G/T) polymorphism with RA and SLE patients 23at20 C serumwas assessed for complement level (C3 and C4)
by using single radial immunodiffusion plates (FAR Ven
Fermi, 12-Italy), antinuclear antibodies (ANA) (Generic
Assays, Germany) by ELISA and anti-double stranded
deoxyribonucleic acid (anti-dsDNA) by (Elabscience,
Biotechnology, China) ELISA kits; concentrations >25 IU/ml
and >26 IU/ml were considered positive, respectively.
Assays were performed according to the manufacturer’s
instructions.
2.4. Analysis of the rs7574865 STAT4 polymorphism
DNA was extracted from whole blood in EDTA tubes by using
GeneJET Whole Blood Genomic DNA Puriﬁcation Mini Kit
(Thermo Scientiﬁc, Waltham, Massachusetts, USA) according
to the protocol provided by the manufacturer. The extracted
DNA was stored at 20 C until analyzed. The upstream pri-
mer 50-AAA GAA GTG GGA TAA AAA GAA GTT TG-30
and the downstream primer 50-CCA CTG AAA TAA GAT
AAC CAC TGT-30 was used to generate a region of 147 bp
of the STAT4 gene. Brieﬂy, PCR was carried out using 20 pmol
of each primer (Biosearch Technologies, South McDowell
Blvd, Petaluma, USA), 200 lM dNTPs, 1.5 mM MgCl2, 1U
Taq DNA polymerase enzyme in a 1· PCR buffer (Thermo
Scientiﬁc Maxima Hot Start PCR Master Mix Waltham, Mas-
sachusetts, USA) and 300–500 ng genomic DNA in a total vol-
ume of 25 ll. The PCR protocol consisted of 5 min at 95 C, 35
cycles at 95 C for 30 s, 56 C for 30 s, 72 C for 1 min and then
a ﬁnal extension at 72 C for 5 min. The 147-bp PCR products
were digested by a 3-h restriction enzyme HpaI at 37 C
(Thermo Scientiﬁc, Waltham, Massachusetts, USA), which
digests the ampliﬁed DNA from the minor T allele into 122-
bp and 25-bp fragments (invisible band) whereas the STAT4
G allele remained uncut. Both undigested and digested PCR
products were visualized in 2.5% agarose gel stained with
ethidium bromide [26].
Statistical analysis: Data were analyzed using a statistical
package of social science (SPSS) version 21. Results for contin-
uous variables were expressed as mean ± SD. Qualitative data
were expressed as frequency and percentage. Normally dis-
tributed numerical data were analyzed by a one-way analysis
of variance (ANOVA). Non-parametric numerical data were
analyzed using Kruskal–Wallis test. Chi-square test or Fisher’s
exact test was used to examine the relation between qualitative
variables. A p-Value less than 0.05 was considered signiﬁcant.
Unconditional logistic regression analysis was used to
calculate odds ratios (OR) and 95% conﬁdence intervals (CI)
for risk estimation.
3. Results
3.1. Association of STAT4 (rs7574865) polymorphisms
genotypes with RA and SLE susceptibility
In both RA and SLE patients, the frequencies of STAT4 (GT)
genotype were signiﬁcantly increased compared to controls
(46%, 48% versus 26%) respectively. The frequency of the T
allele of STAT4 was signiﬁcantly increased in RA and SLE
compared to controls (37%, 40% versus 17%). There was no
signiﬁcant difference between RA and SLE patients as regards
STAT4 genotypes and the T allele. Moreover, patients thatcarried the T allele were signiﬁcantly more likely to develop
RA (OR= 2.6, 95% CI = 1.6–4.2, p= 0.0001) and SLE
(OR= 3.07, 95% CI = 1.9–4.8, p= 0.0001) (Table 1).
3.2. Relation between gene polymorphism and clinical and
laboratory data of RA patients
STAT4 TT genotypes showed a signiﬁcant association with
ESR, CRP, HAQ, DAS28, AntiCCP+, number of tender
joints and modiﬁed Sharp/van der Heijde score as compared
to the STAT4 GG genotype. On the contrary, none of the
other disease activity parameters showed any correlation.
Also 85% (6/7), 100% (7/7) of the homozygous T genotype
was positive for RF and anti-CCP respectively (Table 2).
3.3. Relation between gene polymorphism and clinical and
laboratory data of SLE patients
STAT4 GT and TT genotypes showed a signiﬁcant increase in
levels of proteinuria (mg/24 h), positive anti-dsDNA cases,
decrease in levels of C3, C4, photosensitivity and damage
index as compared to the STAT4 GG genotype patients. On
the contrary none of the other disease clinical features showed
any signiﬁcant correlation. Also 100% (8/8) of homozygous T
genotype was positive for ANA and anti-dsDNA respectively
(Table 3).
Fig. 1 shows the restriction fragment length polymor-
phism–polymerase chain reaction (RFLP-PCR) analysis of
STAT4 gene polymorphism with HpaI separated on an agrose
gel.
4. Discussion
The association of STAT4 polymorphism is determined in sev-
eral autoimmune diseases including SLE [11,19], type I dia-
betes [26,27], primary Sjogren’s syndrome [28], juvenile
idiopathic arthritis [29], Crohn’s disease [30] and psoriasis
[31]. Moreover, several studies proved a strong linkage
between STAT4 polymorphism and RA risk in different ethnic
groups [32,33]. This study was done to investigate the associa-
tion of a STAT4 rs7574865 (G/T) polymorphism with RA and
SLE in Egyptian patients and its signiﬁcance in relation to dis-
ease activity and severity.
In the present study STAT4 rs7574865gene polymorphism
revealed that GT and TT genotypes were signiﬁcantly higher
among RA and SLE patients than in controls. On the con-
trary, GG genotype was signiﬁcantly less frequent. So, there
was increased frequency of the T carrier and the T allele in
RA and SLE patients than in control which means that indi-
viduals with the T allele were at a signiﬁcant positive risk for
RA and SLE compared with the G allele. Other studies deter-
mined the strong association between STAT4 rs7574865 poly-
morphism and RA in European [12] and Egyptian populations
[34]. However, these ﬁndings are not consistent with the study
of Li et al. [35] who found that STAT4rs7574865 was not asso-
ciated with RA in the Chinese Han population. Also STAT4
(rs7574865) has been conﬁrmed as a genetic risk factor for
SLE in Colombians, Mexicans and Argentinean cohorts [36]
and in Iranian population [37]. However, these ﬁndings are
not consistent with the study of Zervou et al. [38] who found
that STAT4rs7574865 was not associated with the Turkish
Table 1 The distribution of STAT4 rs7574865 polymorphism (G/T) genotypes and alleles in the studied groups.
Genotype/alleles n (%) Patients Control (n= 50) RA vs Controls SLE vs controls
RA (n= 50) SLE (n= 50) v2 p-value OR (95% CI) v2 p-value OR (95% CI)
Genotype GG 20 (40) 18 (36) 35 (70) – 1 (referent) – 1 (referent)
GT 23 (46) 24 (48) 13 (26) 12.5 2.9 15.31 3.3
0.0004* (1.6–5.5) 0.0001* (1.8–6.2)
TT 7 (14) 8 (16) 2 (4) 9.27 4.9 14.09 6.6
0.002* (1.6–14.6) 0.0006* (2.3–19.3)
p-Value 0.91
Allele G 63 (63) 60 (60) 83 (83) – 1 (referent) – 1 (referent)
T 37 (37) 40 (40) 17 (17) 18.03 2.6 3.1 3.1
0.0001* (1.6–4.2) 0.0001* (1.9–4.8)
p-Value 0.77
RA: rheumatoid arthritis, SLE: systemic lupus erythematosus, OR: odds ratio, CI: conﬁdence interval.
* Signiﬁcant at p< 0.05.
Table 2 Association of STAT4 rs7574865 (G/T) polymorphism with various parameters of RA.
Clinical features Genotype in RA patients (n= 50) p
GG (n= 20) GT (n= 23) TT (n= 7)
Age (years) 39.85 ± 13.7 39.86 ± 14 40.21 ± 11.7 0.9
Disease duration (years) 4.41 ± 4.19 5.25 ± 4 6.63 ± 0.4 0.14
ESR (mm/h) 45.62 ± 36.4 48.43 ± 30.7 65.28 ± 46.1 0.041*
CRP (mg/dl) 35.85 ± 57.6 38.74 ± 67.3 132.0 ± 150.4 0.03*
No. of swollen joints 2.52 ± 2.1 2.78 ± 1.86 3.7 ± 2.5 0.18
No. of tender joints 6.58 ± 3.6 8.70 ± 5.1 16.07 ± 4 <0.001*
DAS 28 4.20 ± 1.05 5.11 ± 1.11 7.72 ± 1.57 0.023*
MHAQ 0.98 ± 0.6 1.51 ± 0.8 2.04 ± 1.3 0.037*
RF+ 41 (82) 16 (80) 19 (82.6) 6 (85.7) 0.939
AntiCCP + 45 (90) 15 (75) 23 (100) 7 (100) 0.015*
Modiﬁed SvH score 40.5 [20–80] 52.5 [35–90] 70.5 [20–102] 0.0001*
ESR: erythrocyte sedimentation rate, CRP: C-reactive protein, DAS-28: Disease Activity Score 28-joint assessment, MHAQ: modiﬁed Health
Assessment Questionnaire, RF+: rheumatoid factor positive cases, Anti-CCP+: anti-cyclic citrullinated peptides, SvH: Sharp/van der Heijde.
Values are presented as mean ± SD, n (%) or median[range].
* Signiﬁcant at p< 0.05.
24 H.M. El-Saadany et al.SLE patients; this may be due to different ethnic groups. Also
Raafat et al. [14] found that STAT4 (G/T) polymorphism was
not associated with an increased risk of SLE in Egyptian
females, this may be attributed to the difference in the method
of genotyping that was performed by the real time PCR-allelic
discrimination technique in the previous study.
In this study the frequency of the T allele of STAT4
rs7574865 in healthy controls of Egyptian populations was
17%, comparable to another study done for the same popula-
tions [34] but slightly lower when compared to other studies
for Caucasians (22%) [12], Japanese and Chinese populations
(30–34%) [11,39], as there are differences in the various ethnic
groups. T allele frequency in our RA and SLE patients showed
a signiﬁcant increase in comparison with healthy controls. The
present ﬁndings seem to be consistent with other studies that
also found a signiﬁcant difference of the allele frequency
between RA, SLE patients and healthy controls in North
American, European [19], Japanese [11] and Colombian [13]
patients. The increased frequency of the TT genotype and
the T allele in RA and SLE patients came in agreement with
results of Remmers et al., [19] and Ji et al. [32].In this work there was a signiﬁcant association of the T
allele of STAT4 rs7574865 with high levels of ESR, CRP, num-
ber of tender joints, DAS28, HAQ and the presence of anti-
CCP antibodies in RA patients. This in agreement with Shen
et al. [40] who found that STAT4 rs7574865 GT genotype
was evident among RF positive patients, with higher ESR
levels and DAS28 compared with the GG genotype thus sug-
gesting that this polymorphism may be associated with the
active forms of RA. However Kobayashi et al. and Mohamed
et al. [11,34] found no signiﬁcant differences among the geno-
types as regards these disease activity parameters.
As for RA-related autoantibodies, T allele of STAT4
rs7574865 was observed signiﬁcantly in RA patients regarding
the positivity of RF or anti-CCP antibodies as compared with
patients that carried the G allele, this is in agreement with
studies for the Korean population [10], Chinese Hans popula-
tion [35] and Egyptian populations [34]. However, another
study done for the Spanish cohort found that STAT4 is a risk
factor for RA, independent of the presence of serum autoanti-
body [12]. The results obtained in this study suggest that RA
patients with TT genotypes were signiﬁcantly associated with
Table 3 Association of STAT4 rs7574865 (G/T) polymorphism with the studied parameters in SLE patients.
Clinical features Genotype in SLE patients (n= 50) p
GG (n= 18) GT (n= 24) TT (n= 8)
Age (years) 27.44 ± 7.25 27 ± 7.08 30.6 ± 4.8 0.16
Disease duration (years) 5.41 ± 2.23 4.74 ± 3.25 5.12 ± 2.25 0.46
Proteinuria (mg/24 h) 698.9 ± 807.3 1189.3 ± 1215.9 1346.41 ± 1616 0.01*
ANA+ 48 (96) 14 (77.8) 22 (91.7) 8 (100) 0.7
Anti-dsDNA+ 49 (98) 17 (94.4) 24 (100) 8 (100) 0.034*
C3 level (mg/dl) 58.1 ± 14.5 51.32 ± 17.55 31.34 ± 11.8 0.047*
C4 level (mg/dl) 16.9 ± 3.95 10.3 ± 2.88 6.61 ± 2.08 0.001*
Photosensitivity 40 (80) 16 (88.9) 18 (75) 6 (75) 0.03*
Oral ulcer 12 (48) 2 (11.1) 6 (25) 4 (50) 0.8
Arthritis 30 (60) 10 (55.6) 14 (58.3) 6 (75) 0.57
Serositis 14 (28) 6 (33.3) 6 (25) 2 (25) 0.6
Seizures 8 (15) 2 (11.1) 4 (16.7) 2 (25) 0.3
SLEDAI score 17.21 ± 1.42 18.65 ± 2.54 19.65 ± 2.5 0.19
Damage index 4.3 ± 1.09 8.54 ± 2.12 10.54 ± 2.87 0.001*
ANA: antinuclear antibody, anti-dsDNA: anti-double stranded DNA, C3, C4: serum complement level, SLEDAI: SLE disease activity index
score. Values are presented as mean ± SD or n (%).
* Signiﬁcant at p< 0.05.
Figure 1 Restriction fragment length polymorphism–polymerase chain reaction (RFLP-PCR) analysis of STAT4 gene polymorphism
with HpaI separated on an agrose gel. Lane 1: represents a 50 bp marker ladder (GeneRuler 50 bp DNA Ladder) (50–1000 bp) served as
reference for DNA fragment size. Lanes 2,4,6,7,8,10,11: show 3 bands at 25 bp, 122 bp and 147 heterozygous for the absence and presence
of restriction site (GT) (only 2 bands are apparent because the band at 25 bp is difﬁcult to be seen). Lanes 3,5,12,13: show one band at
147 bp homozygous for the absence of restriction site (GG). Lane 9: shows 2 bands at 25 bp and 122 bp homozygous for the presence of
restriction site (TT) (only one band is apparent because the band at 25 bp is difﬁcult to be seen). See comment in PubMed Commons
below.
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vious studies of Mohamed et al. and Lamana et al. [34,41] who
suggested that patients who are homozygous for the T allele of
rs7574865 in STAT4 may develop a more severe form of the
disease with increased disease disability.
For SLE patients, the present study showed that a minor T
allele in rs7574865 correlated with proteinuria, C3, C4 levels,anti-dsDNA positivity and damage index. This comes in accor-
dance with previous studies that found an association between
the minor T allele in rs7574865 and different SLE clinical fea-
tures such as nephritis, anti-dsDNA antibody [42–44]. This
study showed that SLE patients with a TT homozygous had
higher ANA and anti-dsDNA positivity compared to other
genotypes. This is in accordance with Raafat et al. [14] who
26 H.M. El-Saadany et al.found that 100% of TT genotypes were positive for ANA and
anti-dsDNA antibodies. Also Chung et al. [45] and Zheng
et al. [33] reported a strong association between STAT4
rs7574865 polymorphism and anti-dsDNA positive SLE. So
the T allele of STAT4 is related strongly to autoantibody for-
mation in both RA and SLE. However, other studies found no
signiﬁcant association between STAT4 and the clinical features
of SLE [37,46]. Also, a meta-analysis found that the T allele or
TT homozygous is a signiﬁcant risk genetic molecular marker
to predict SLE susceptibility but the association was not found
for lupus nephritis [47]. Possible explanations for these ﬁndings
might be different ethnic groups, variable SLE clinical features
and different sizes of the studied groups. However prospective
studies from different populations should be carried out to
deﬁne the association of STAT4 (G/T) polymorphism with
the laboratory and clinical features of both RA and SLE
patients.
In conclusion, STAT4 rs7574865 (G/T) polymorphism is
associated with an increased risk of the development of RA
and SLE in Egyptian patients. This may indicate that STAT
is a common genetic risk factor for both diseases. Moreover
RA, SLE patients who are homozygous for the T allele are sus-
ceptible to have increased disease activity and severity. How-
ever, more studies are still needed for the same population
on larger scales to prove the relation of this polymorphism
and both the severity and activity of RA and SLE.
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